Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373–9.
Taguchi S, Fukuhara H, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. Jpn J Clin Oncol. 2019;49(3):201–9.
Bommareddy PK, Shettigar M. Kaufman HL Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18:498–513.
Fukuhara H, Takeshima Y, Todo T. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors. Cancer Sci. 2021;112(8):3293–301.
Zeng J, Li X, Sander M, et al. Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas. Front Immunol. 2021;12: 721830.
Kaufman HL, Bommareddy PK. Two roads for oncolytic immunotherapy development. J Immunother Cancer. 2019;7:26.
Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy. Hum Vaccines Immunother. 2020;16(10):2389–402.
Ghouse JN, Martuza SM, Rabkin SD. In situ cancer vaccination and immunovirotherapy using oncolytic HSV. Viruses. 2021;13:1740.
Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1(9):938–43.
Otani Y, Yoo JY, Shimizu T, et al. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma. Brain Tumor Pathol. 2022;39(2):57–64.
Todo T, Ito H, Ino Y, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28:1630-9.
Article PubMed PubMed Central Google Scholar
UMIN Clinical Trials Registry. Unique UMIN ID UMIN000015995. http://upload.umin.ac.jp. Accessed 29 July 2022.
Daiichi Sankyo Co. Ltd. DELYTACT® oncolytic virus G47∆ approved in Japan for treatment of patients with malignant glioma [media release]. 11 June 2021. https://www.daiichisankyo.com.
Daiichi-Sankyo Co. Ltd. DELYTACT: Japanese package insert. 2021.
Daiichi Sankyo Co. Ltd. Daiichi Sankyo launches DELYTACT(R) oncolytic virus G47 delta in Japan [media release]. 1 Nov 2021. https://www.daiichisankyo.com.
Daiichi Sankyo Co. Ltd. Oncolytic virus G47delta (DS-1647) designated as orphan drug under Orphan Drug/Medical Device designation system [media release]. http://www.daiichisankyo.com. Accessed 19 July 2021.
Daiichi Sankyo Co. Ltd. Daiichi Sankyo submits application for oncolytic virus teserpaturev (G47Δ) for treatment of patients with malignant glioma in Japan [media release]. http://www.daiichisankyo.com. Accessed 19 July 2021.
Daiichi Sankyo Co. Ltd. Reference data (consolidated financial results for Q3 FY2020). http://www.daiichisankyo.com. Accessed 29 July 2022.
Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA. 2001;98:6396–401.
Zhang W, Fulci G, Wakimoto H, et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia. 2013;15(6):591–9.
Barnard Z, Wakimoto H, Zaupa C, et al. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 2012;71(3):741–8.
Hoffmann D, Wildner O. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment. Cancer Gene Ther. 2007;14(7):627–39.
Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69(8):3472–81.
Cheema TA, Wakimoto H, Fecci PE, et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci USA. 2013;110(29):12006–11.
Cheema TA, Kanai R, Kim GW, et al. Enhanced antitumor efficacy of low-dose etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res. 2011;17(23):7383–93.
Ning J, Wakimoto H, Peters C, et al. Rad51 degradation: role in oncolytic virus-poly(ADP-ribose) polymerase inhibitor combination therapy in glioblastoma. J Natl Cancer Inst. 2017;109(3):1–13.
Kanai R, Rabkin SD, Yip S, et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012;104(1):42–55.
Nigim F, Esaki S, Hood M, et al. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro Oncol. 2016;18(9):1278–87.
Saha D, Wakimoto H, Peters CW, et al. Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models. Clin Cancer Res. 2018;24(14):3409–22.
Esaki S, Nigim F, Moon E, et al. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017;141(11):2348–58.
Farrell CJ, Zaupa C, Barnard Z, et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res. 2008;14(23):7711–6.
Sugawara K, Iwai M, Ito H, et al. Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition through dynamic intratumoral immune modulation. Mol Ther Oncol. 2021;22:129–42.
Fan J, Jiang H, Cheng L, et al. Oncolytic herpes simplex virus and temozolomide synergistically inhibit breast cancer cell tumorigenesis in vitro and in vivo. Oncol Lett. 2021;21(2):99.
Sugawara K, Iwai M, Yajima S, et al. Efficacy of a third-generation oncolytic herpes virus G47Δ in advanced stage models of human gastric cancer. Mol Ther Oncol. 2020;17:205–15.
Fan J, Jiang H, Cheng L, et al. The oncolytic herpes simplex virus vector, G47Δ, effectively targets tamoxifen-resistant breast cancer cells. Oncol Rep. 2016;35(3):1741–9.
Wang L, Ning J, Wakimoto H, et al. Oncolytic herpes simplex virus and PI3K inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells. Mol Ther Oncol. 2019;13:58–66.
Yamada T, Tateishi R, Iwai M, et al. Neoadjuvant use of oncolytic herpes virus G47Δ enhances the antitumor efficacy of radiofrequency ablation. Mol Ther Oncol. 2020;18:535–45.
Ito H, Ino Y, Todo T. Therapeutic efficacy of third generation oncolytic HSV-1 (G47delta) for glioma cells with stem cell property [abstract]. In: 19th annual meeting of the American Society of Gene and Cell Therapy, 2016.
Saha D, Martuza RL, Rabkin SD. Glioblastoma eradication by combination oncolytic immunovirotherapy and immune checkpoint blockade [abstract]. Mol Ther. 2017;25(5 Suppl 1):361.
Uchihashi T, Nakahara H, Fukuhara H, et al. Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis. Mol Ther Oncol. 2021;22:388–98.
Yajima S, Sugawara K, Iwai M, et al. Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma. Mol Ther Oncol. 2021;23:402–11.
Inoue K, Ito H, Iwai M, et al. Neoadjuvant use of oncolytic herpes virus G47delta prevents stage advancement of tongue cancer. Cancer Sci. 2022;113:1422.
Cheema TA, Fecci PE, Ning J, et al. Immunovirotherapy for the treatment of glioblastoma. OncoImmunology. 2014;3(1): e27218.
Esaki S, Rabkin SD, Martuza RL, et al. Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. Am J Cancer Res. 2016;6(2):300–11.
CAS PubMed PubMed Central Google Scholar
Saha D, Rabkin SD, Martuza RL. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. J Immunother Cancer. 2020;8(Suppl 1): e000345.
Todo T, Ino Y, Ohtsu H, et al. A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma. Nat Commun. 2022;13(1):4119.
Todo T. Results of phase ii clinical trial of oncolytic herpes virus G47delta in patients with glioblastoma [abstract no. ATIM-14]. Neuro Oncol. 2019;21(Suppl 6):vi4.
留言 (0)